United States:
Amneal Launches RELEUKO (filgrastim-ayow) In The United States
25 November 2022
Goodwin Procter LLP
To print this article, all you need is to be registered or login on Mondaq.com.
On November 22, 2022, Amneal Pharmaceuticals, Inc.
("Amneal") announced the commercial launch of RELEUKO, a
biosimilar referencing Neupogen. RELEUKO is used to treat
neutropenia which is commonly experienced by patients undergoing
chemotherapy. RELEUKO is Amneal's second U.S. biosimilar
launch. As we previously reported, Amneal announced the launch of its first biosimilar
in the U.S., ALYMSYS (bevacizumab-maly), on October 3, 2022.
According to the release, RELEUKO "represents the next step in
building out [Amneal's] biosimilars business."
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Healthcare Trends & Transactions Q3 2023
Bass, Berry & Sims
After steadying during Q2, it appears the overall volume of deals in the healthcare industry declined in Q3 compared with Q2, and year-to-date 2023 is still down from last year.
Telehealth Providers: HHS Issues HIPAA Best Practices
Foley & Lardner
Recognizing the evolving landscape of care delivery and growth of telehealth, the U.S. Department of Health and Human Services (HHS)published a resource guide aimed at assisting telehealth providers...